Humoral and cellular immunity
| . | Patient 1 . | Patient 2 . | Control or normal range . |
|---|---|---|---|
| Markers; % (count) | |||
| CD2 | 8 (143) | 8.4 (421) | 75-96 |
| CD3 | 0.2 (4) | 0.4 (9) | 60-85 |
| CD4 | 0 (0) | 0.5 (4) | 30-60 |
| CD8 | 0.1 (2) | 0 (0) | 15-35 |
| CD56 | 6 (125) | 14 (711) | 5-20 |
| CD16 | 15 (277) | 7 (352) | 5-20 |
| CD19 | 81 (1493) | 76 (4074) | 2-20 |
| Mitogenic responses; counts × 10−3 | |||
| Phytohemagglutinin (PHA) | 1.3 | 0.7 | 90-130 |
| Anti-CD3 | 2.5 | 1.0 | 35-55 |
| Staphylococcus aureus Cowan A | 11.0 | 90.6 | 10-60 |
| Serum immunoglobulins; g/L | |||
| IgG | 0.5 | 1.7 | 2.3-14.1 |
| IgM | 0.1 | < 0.1 | 0.0-1.4 |
| IgA | 0.1 | 0.1 | 0.0-0.8 |
| . | Patient 1 . | Patient 2 . | Control or normal range . |
|---|---|---|---|
| Markers; % (count) | |||
| CD2 | 8 (143) | 8.4 (421) | 75-96 |
| CD3 | 0.2 (4) | 0.4 (9) | 60-85 |
| CD4 | 0 (0) | 0.5 (4) | 30-60 |
| CD8 | 0.1 (2) | 0 (0) | 15-35 |
| CD56 | 6 (125) | 14 (711) | 5-20 |
| CD16 | 15 (277) | 7 (352) | 5-20 |
| CD19 | 81 (1493) | 76 (4074) | 2-20 |
| Mitogenic responses; counts × 10−3 | |||
| Phytohemagglutinin (PHA) | 1.3 | 0.7 | 90-130 |
| Anti-CD3 | 2.5 | 1.0 | 35-55 |
| Staphylococcus aureus Cowan A | 11.0 | 90.6 | 10-60 |
| Serum immunoglobulins; g/L | |||
| IgG | 0.5 | 1.7 | 2.3-14.1 |
| IgM | 0.1 | < 0.1 | 0.0-1.4 |
| IgA | 0.1 | 0.1 | 0.0-0.8 |